Skip to main content
Smart Investors Daily
SR

NASDAQ · SRZN

Surrozen, Inc.

Healthcare · Biotechnology

$24.01

Up+$0.30 (+1.27%)

Updated Aug 28, 2026, 12:58 PM

SID Score

5.8/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
201.6M
P/E ratio
-12.03
Dividend yield
0.00%
52-week range
$10.73 – $35.00
Volume
340.75K
Avg. volume
63.79K

Price performance

SRZN price history

1M range · 0 trading sessions · Daily adjusted prices

SRZN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest SRZN news

The latest Smart Investors Daily articles mentioning SRZN.

SRZN research

Overview

Company profile and research snapshot.

Company profile

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$38.50
Implied upside
Analysts
8
SRZN recent ratings
DateFirmRatingTarget
Aug 20, 2026William BlairOutperform
Aug 10, 2026HC Wainwright & Co.Buy
May 7, 2026HC Wainwright & Co.Buy
Apr 21, 2026TD CowenBuy
Mar 24, 2026HC Wainwright & Co.Buy
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 25, 2025

Surrozen to Present at Upcoming Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences. 37th Annual Piper Sandler Healthcare Conference on December 2, 2025Surrozen Fireside Discussion at 6:30 AM Pacific Time/9:30 AM Eastern T

globenewswire.com · Nov 25, 2025

Surrozen to Present at Upcoming Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.